Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Long-term Safety of ADYNOVI/ADYNOVATE (Antihaemophilic Factor [Recombinant] PEGylated, Rurioctocog Alfa Pegol) in Patients With Haemophilia A - An ADYNOVI/ADYNOVATE Post-Authorisation Safety Study (PASS)

NCT04158934 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT04158934
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04158934 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Long-term Safety of ADYNOVI/ADYNOVATE (Antihaemophilic Factor [Recombinant] PEGylated, Rurioctocog Alfa Pegol) in Patients With Haemophilia A - An ADYNOVI/ADYNOVATE Post-Authorisation Safety Study (PASS)
Lead sponsor
Baxalta now part of Shire
Phase
Observational
Overall status
Active, not recruiting
Start date
July 9, 2020
Completion date
February 28, 2030
Enrollment
207 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a